Patient portrayal.
Individual results may vary.
Dosing &
Administration
How does dosing fit into the story?
5 MG
10 MG
20 MG
Tablets shown not actual size.
For additional dosing information, please see the Full Prescribing Information.
Drug interactions
Clinically important drug interactions with TRINTELLIX1
Drug Class | Clinical Impact & Recommendations |
Monoamine Oxidase Inhibitors selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue |
CONCOMITANT USE WITH TRINTELLIX MAY INCREASE THE RISK OF SEROTONIN SYNDROME MAOIs for psychiatric disorders are contraindicated with TRINTELLIX or within 21 days of stopping TRINTELLIX. TRINTELLIX is contraindicated within 14 days of stopping MAOIs for psychiatric disorders. Starting TRINTELLIX in patients on linezolid or IV methylene blue is also contraindicated. |
Other Serotonergic Drugs SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, St. John’s Wort |
CONCOMITANT USE WITH TRINTELLIX MAY INCREASE THE RISK OF SEROTONIN SYNDROME Monitor for serotonin syndrome when TRINTELLIX is coadministered with other serotonergic drugs. If serotonin syndrome occurs, discontinue TRINTELLIX and other serotonergic drugs, and initiate supportive treatment. |
Strong CYP2D6 Inhibitors bupropion, fluoxetine, paroxetine, quinidine |
CONCOMITANT USE WITH TRINTELLIX MAY INCREASE TRINTELLIX PLASMA LEVELS Reduce the TRINTELLIX dose by half. When discontinuing a strong CYP2D6 inhibitor, increase TRINTELLIX to its original dose. |
Strong CYP Inducers rifampin, carbamazepine, phenytoin |
CONCOMITANT USE WITH TRINTELLIX DECREASES TRINTELLIX PLASMA LEVELS Consider increasing the dose of TRINTELLIX when coadministered for more than 14 days. The maximum TRINTELLIX dose should not be greater than three times the original TRINTELLIX dose. When discontinuing a strong CYP inducer, reduce TRINTELLIX within 14 days to its original dose. |
Antiplatelet Drugs and Anticoagulants aspirin, NSAIDs, clopidogrel, heparin, warfarin |
CONCOMITANT USE WITH TRINTELLIX MAY POTENTIATE BLEEDING RISK Inform patients of increased bleeding risk. For patients on warfarin, monitor INR carefully when initiating, titrating or discontinuing TRINTELLIX. |
Drugs Highly Bound to Plasma Protein warfarin |
CONCOMITANT USE WITH TRINTELLIX MAY INCREASE FREE TRINTELLIX PLASMA LEVELS OR OTHER HIGHLY PROTEIN-BOUND DRUG LEVELS Monitor for adverse reactions. Reduce dosage of TRINTELLIX or other highly protein-bound drugs as needed. |
Note: Class examples do not include all possible class members.
Abbreviations: INR, International Normalized Ratio; IV, Intravenous; MAOIs, Monoamine oxidase inhibitors; NSAIDs, Nonsteroidal anti-inflammatory drugs; SNRIs, Serotonin-norepinephrine reuptake inhibitors; SSRIs, Selective serotonin reuptake inhibitors.
For additional Drug Interactions information, please see the Full Prescribing Information.
Tools for your patients and practice
Long-term
clinical data
Results from multiple clinical studies of TRINTELLIX.
Prescription
savings for your
eligible patients
Find out about savings and support offered through tAccess by reading the Savings Card brochure.
Offering
patients once
daily dosing
Learning about dosage amounts and drug interactions.
Telling patients
about telehealth
As telehealth visits become more common, it’s important to have helpful resources for you and your patient.
Safety profile
See how the safety profile fits in the story.
Helping patients access savings info and support
Discover resources that may help your patients with savings and more.
Request a
rep visit
Connect with a TRINTELLIX representative.
Patient coverage
in your area
Find out about formulary coverage in your area for TRINTELLIX.
Support for
your patients
We’re here to help your eligible patients get the treatment you prescribe.
Patient profile
Learn more about a patient
living with MDD.
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at